Is evantumumab included in the medical insurance catalog?

Amivantamab is a fully humanized IgG1 monoclonal antibody drug targeting the dual targets of EGFR and MET. It is designed to treat patients with non-small cell lung cancer (NSCLC) carrying exon 20 insertion mutations of the EGFR gene. This type of mutation is relatively more common in Asian populations, and traditional EGFR tyrosine kinase inhibitors (TKIs) have limited effect on it. Therefore, the advent of evantumumab provides a new treatment option for these patients. It plays multiple anti-tumor mechanisms by blocking EGFR and MET signaling pathways, inducing tumor cell apoptosis and enhancing immune effector functions, and has a unique position in the treatment of drug-resistant lung cancer.

In early 2025, evantumumab has been approved by the China National Medical Products Administration and officially launched in China for the treatment of adult patients with advanced or metastatic NSCLC with EGFR exon20 insertion mutations who have received systemic therapy. As one of the important developments in precision treatment of lung cancer in recent years, this drug has attracted widespread attention from the medical community and patient groups once it was launched. However, due to the short time to market, limited accumulation of clinical data and the lag in the medical insurance negotiation cycle, evantumumab has not yet been included in China's medical insurance catalog, which means that patients have to bear its higher drug costs out of their own pocket.

In terms of price, since evantumumab is an original innovative drug and there is no generic version, its market price is relatively high. According to feedback from some pharmacies, the price of its original 350mg injection in Hong Kong is about RMB 10,000, while the price of the European or American versions may even exceed RMB 20,000. This may pose a greater burden for patients with long-term treatment or limited financial conditions. Therefore, many patients currently use the drug selectively according to doctors' recommendations, or find more cost-controllable drug supply channels throughother ways.

Reference materials:https://www.rybrevant.com/